Microbot Medical Sells Unregistered Equity, Dilution Risk Looms

TL;DR

**Microbot Medical just sold new shares, expect potential dilution.**

AI Summary

Microbot Medical Inc. entered into a material definitive agreement on December 29, 2023, involving the unregistered sale of equity securities. This filing indicates the company is raising capital by issuing new shares, which could dilute the value of existing shares. For current or prospective shareholders, this matters because an increase in the number of outstanding shares typically reduces the earnings per share and ownership percentage for existing investors, potentially impacting the stock price negatively.

Why It Matters

This filing signals potential dilution for existing shareholders as Microbot Medical Inc. is selling new equity securities, which could impact the stock's per-share value.

Risk Assessment

Risk Level: medium — The unregistered sale of equity securities introduces dilution risk for current shareholders, which can negatively impact stock price.

Analyst Insight

A smart investor would monitor Microbot Medical Inc.'s stock for potential price drops due to dilution and evaluate the terms of the material definitive agreement once disclosed to understand the full impact on shareholder value.

Key Players & Entities

• Microbot Medical Inc. (company) — registrant selling equity securities
• December 29, 2023 (date) — date of earliest event reported
• Delaware (company) — state of incorporation for Microbot Medical Inc.
• 000-19871 (company) — Commission File Number for Microbot Medical Inc.
• 94-3078125 (company) — IRS Employer Identification No. for Microbot Medical Inc.

Forward-Looking Statements

• Microbot Medical Inc.'s stock price may experience downward pressure due to dilution from the unregistered equity sales. (Microbot Medical Inc.) — medium confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.01 — nge on which registered Common Stock, $0.01 par value MBOT NASDAQ Capital Mark
• $2.20 — 's common stock at an exercise price of $2.20 per share, issued on October 25, 2022,
• $2.075 — 's common stock at an exercise price of $2.075 per share, issued on June 6, 2023, and
• $3.19 — 's common stock at an exercise price of $3.19 per share issued on June 26, 2023 (toge
• $1.62 — stock, at a reduced exercised price of $1.62 per share, in consideration for the Com
• $2.73 million — gregate gross proceeds of approximately $2.73 million from the exercise of the Existing Inves
• $60,000 — any also agreed to pay Wainwright up to $60,000 for non-accountable expenses, and $15,9
• $15,950 — 0,000 for non-accountable expenses, and $15,950 for clearing fees. The Company also agr
• $2.025 — s except for an exercise price equal to $2.025 per share. Further, pursuant to the Eng
• $1.50 — on will have an exercise price equal to $1.50 per share. The Inducement Investment Op

Filing Documents

• form8-k.htm (8-K) — 60KB
• ex4-1.htm (EX-4.1) — 136KB
• ex4-2.htm (EX-4.2) — 135KB
• ex10-1.htm (EX-10.1) — 63KB
• ex99-1.htm (EX-99.1) — 14KB
• 0001493152-24-000109.txt ( ) — 658KB
• mbot-20231229.xsd (EX-101.SCH) — 3KB
• mbot-20231229_lab.xml (EX-101.LAB) — 33KB
• mbot-20231229_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 3KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. MICROBOT MEDICAL INC. /s/ Harel Gadot Harel Gadot Chairman, President and Chief Executive Officer Date: January 2, 2024

View Full Filing

View this 8-K filing on SEC EDGAR